ResearcherDalhousie UniversityNo recent work listed

David M. Waisman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5097-9662; OpenAlex author ID A5091852858. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper

Papers 2

S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/1878-0261.12356 ↗
Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Co-author DOI 10.1038/cddis.2013.307 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Moamen Bydoun · 1 shared paper, 2018 · strength 0.08
- Paper S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. DOI 10.1002/1878-0261.12356 ↗
Weei‐Yuarn Huang · 1 shared paper, 2018 · strength 0.08
- Paper S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. DOI 10.1002/1878-0261.12356 ↗
P W K Lee · 1 shared paper, 2013 · strength 0.04
- Paper Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer … DOI 10.1038/cddis.2013.307 ↗
Richard Hill · 1 shared paper, 2013 · strength 0.04
- Paper Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer … DOI 10.1038/cddis.2013.307 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.